Friday, January 31, 2014

(LML) ILA messages 2014's World Leprosy Day

Leprosy Mailing List – January 31,  2014 

Ref.:   (LML)  ILA messages 2014’s World Leprosy Day

From:  Marcos Virmond, ILSL, Bauru, São Paulo, Brazil


Dear Dr Schreuder,

On behalf of the ILA , I would like to ask if you could disseminate to LML readers two ILA messages related to the 2014’s World Leprosy Day, which are available to your readers at the ILA website as follows:

 http://www.leprosy-ila.org/arquivos/world_leprosy_day_january_2014.pdf

 http://www.leprosy-ila.org/arquivos/ila_awarded_2014.pdf

 

With my best regards,

 

M. Virmond MD, PhD

ILA President


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


Monday, January 27, 2014

(LML) Facial Erythematous Patches

Leprosy Mailing List – January 27 ,  2014 

Ref.:    (LML) Facial  Erythematous  Patches

From:  Grace Warren, Sidney, Australia


 

Dear Pieter,


Yes I would also like to comment on the two lesions shown in the letter from Dr Rao. There were I think both originally stated to be  PB leprosy and treated accordingly.


In one when the lesion returned after the MDT has ceased the patient was treated with steroids only.  I am afraid that will not eliminate the bacilli which, as  Dr Barretto  says,  are hiding in the blood vessels . Yes the steroids reduce the swelling and make it look better but also reduce the effectiveness of the body’s ability to eliminate the bacilli. 

 

I would never treat any leprosy patient who has a reaction with steroids without other antileprosy drugs.  In fact  I always increase the MDT by as many months as they have had the steroid. Yes the steroid reduces the signs of inflammation - and makes the patient feel better,  but it also allows the bacilli freedom of movement and multiplication as the  T-lymphocytes are not so effective against the bacilli when steroids are around.


 Also the appearance of that lesion is certainly not the normal appearance for a true PB - there is too much edge and one suspects that there are more lesions elsewhere.  I always taught the PB was less than 6 lesions yes and must have normal sensation,  BUT if the lesions were scattered on several areas of the body - e.g. one on arm, one of leg one on face  etc then it was better and safer to treat as MB initially. I have seen too many of these so called relapses  which I think could easily be prevented.


This type of lesion is also not uncommon in Eastern Asia - i.e. the lighter skins often  develop a diffuse infiltration that is very difficult to see any edge  and define  one,  but if allowed to persist will eventually be true highly infectious LL/.BL disease.

 

Yes the second lesion of the nose certainly looks  more BT than  Indeterminate. So although it may technically be PB it is far safer to treat as MB.


With many years of experience  I teach that it is far better to overtreat initial lesions if there is any chance of the lesions being MB   and if there is any reaction treat again with full MDT. For those who tend to reaction I like increasing the clofazamine that often is as effective and not as dangerous  as steroids as I found many patient in Asian countries go and buy the steroids themselves because it is freely available in their country and it makes them feel better. I have seen so many people with  undesirable effects, even death, from
OVERuse of steroids. 

 

If steroids were commenced before I see the patient, I like to grade them off the steroids by using clofazamine in higher dosage and then increase the total amount of MDT by the  total number of months that the steroids were used.  Please make sure the patient does not have some other metabolic or infectious disease that could be reducing his immune potential! We must make every effort to prevent relapses as each one of these tends to spread the message we cannot  treat  leprosy  adequately.

 

All the best to those who really care for their patients long term  welfare,
 

Grace Warren

Previously   Superintendent Hong Kong Leprosarium ( 1960-75)
Also  Previously Adviser in Leprosy and Reconstructive Surgery for the Leprosy Mission in Asia ( 1975-1995)


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Clinical leprosy, case report, BL-LL leprosy in ENL reaction

Leprosy Mailing List – January 27,  2014 

Ref.:  (LML)   Clinical leprosy, case report, BL-LL leprosy in ENL reaction

From:  P. Forgione and S. Noto, Naples and Bergamo, Italy


 

Dear Pieter,

 

In attachment are pictures of a young leprosy patient from Bangladesh seen in Naples, Italy.

 

In November 2011 he presented suffering of painful reddish nodules on face and trunk, several macules on all limbs, dry skin on right knee, leg and foot, ichthyosis like skin on right leg, anesthesia and ulcer of the right heel.  Slit-skin smear examination reported a bacteriological index (BI) 4+; morphologic index (MI) 0.8% and globi.  The diagnosis of borderline lepromatous – lepromatous (BL-LL) leprosy in erythema nodosum leprosum (ENL) reaction was made. 

 

He started anti-leprosy and anti reactional treatment.  ENL resolved first but, relapsed later on and became recurrent.  He still is in treatment with low doses of thalidomide.  The ulcer on the foot slowly closed but, relapsed again in 2013.

 

Thank you very much for circulating this case on the LML.

 

P. Forgione and S. Noto


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


Sunday, January 26, 2014

(LML) Facial Erythematous Patches

Leprosy Mailing List – January 26,  2014 

Ref.:    (LML) Facial Erythematous Patches

From:  Jaison Barreto, ILSL, Bauru, São Paulo , Brazil


 

Dear Pieter

 

This has reference to the LML dated 10-1-2014 from Dr PN Rao regarding persistent facial patches. Cases like this are not uncommon in Brazil. This is clearly a case of type 1 reaction in a borderline patient. I see many cases, almost every week, at the national reference I work, and the history is almost always the same: "a referred PB patient with untreatable reaction".

 

One of the most important problem of patients like this is the fact that they are usually treated as having PB leprosy. Most of them have, initially, less than five lesions, i.e., PB leprosy. Many times, the histopathology of these lesions shows a "tuberculoid" pattern (BT). Once Fite-Faraco staining is usually not done, even in most laboratory of histopathology (they use to do only Ziehl staining), in many instances, bacilloscopy of lesion (BBI), unfortunately, does not show the real bacilloscopy (2+ or more). Also, once the bacilloscopy of ear lobes, elbows and knees are negative on these cases, the consequence is a confirmation of the misdiagnosis.

 

When the reaction appears, for these patients (whose are being - or were - treated with PB MDT) only corticosteroid is given. Of course, the dilatation of vessels diminishes, the lesion becomes flattened, and reaction subsides, but the bacilli continue still alive, mainly inside the nerves and smooth muscle. Sometimes, even the bacilloscopy (slit skin smear) of a reactional (BT) lesion does not show bacilli,   once it is not a good idea for M.leprae staying inside an epithelioid cell. 

 

The consequence of this kind of approaching is a vicious circle: reaction, corticosteroids, "improvement" (diminishing of redness), immunnosuppression, M.leprae multiplication, new reaction, new administration of corticosteroids...

Once the time interval of duplication of M.leprae is 14 days, after 5 to 7 years (mean), a bacilloscopy of lesion (and sometimes ear lobes) finally shows bacilli due to a spreading of infection in an initially borderline patient.

 

And the time goes by...

 

Regards

 

Jaison

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Facial Erythematous Patches

Leprosy Mailing List – January 26,  2014 

Ref.:   (LML) Facial Erythematous Patches

From:  V V Pai, Mumbai, India


Dear Dr Pieter

This has reference to the LML dated 10-1-2014 from Dr PN Rao regarding persistent facial patches which pose a therapeutic challenge. We regularly come across such cases at our referral Center, with type I reaction / persistence of lesions on face which is a clinical problem. In our experience patients with type I reaction respond well to a course of steroids but in some lesions persist with erythema. This is also seen in some cases where lesions are generalised including lesions on face and those on the trunk and back respond well while lesions on the face persist for a longer time. Whether photo sensitivity plays a role in persistence of the lesions on face is an area of research.  

 

I agree with Dr Kar therefore that sunscreens are necessary to control the erythema and prevent flare up of the lesions on face. We have observed that such persistent lesions on the face need to be treated with a course of steroids and Clofazimine in anti inflammatory doses, which should be given for six months in tapering manner. One such patient among many others benefited with this regimen is enclosed.  

 

I have published my observations in this regard in Int Journal of Leprosy, Vol 70, No 4, P-120A, Dec 2002.

 

Dr V V Pai

Director

Bombay Leprosy Project 

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


Thursday, January 23, 2014

(LML) ALERT Training Schedule 2014

Leprosy Mailing List – January 23,  2014 

Ref.:    (LML) ALERT Training Schedule 2014

From:  Kalkidan Behailu, ALERT, Addis Ababa, Ethiopia


 

Dear Pieter,

 

 

Could  you be so  kind  to post this on the LML? It is the training summary for 2014 offered at ALERT Training Center in Ethiopia. 

 

Thank you for your help

 

Kalkidan Behailu

Admin/Marketing Assistant

Alert Training Division

Tel +251-118-962277
      +251-113-481517

Fax +251-113-481163

Email: leprosytb@ethionet.et

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) World Leprosy Day, Sunday 26th January 2014

Leprosy Mailing List – January 23,  2014 

Ref.:   (LML)  World Leprosy Day, Sunday 26th January 2014

From:  Felicity Bonham, ILEP, London, UK


Dear Pieter,

 On behalf of Mr René Stäheli, President of ILEP, I am writing to ask if you might disseminate to LML readers his message marking this year’s World Leprosy Day, Sunday 26th January 2014. This is also available for download from the ILEP website: http://goo.gl/7LN6Hz.

Thank you in advance. 

 Best,

 Felicity

Felicity Bonham, PA to the General Secretary

International Federation of Anti-Leprosy Associations
Working together for a world without leprosy

Tel: +44 (0)20 7602 6925 – Fax: +44 (0)20 7371 1621 – Website: www.ilep.org.uk

 

To get our updates, like us on Facebook: ILEPAntiLeprosy


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


Tuesday, January 21, 2014

(LML) Newly Developed Model Patient Card/Record (Leprosy) by ILEP Technical Commission (ITC)

Leprosy Mailing List – January 21,  2014 

Ref.:  (LML)   Newly Developed Model Patient Card/Record (Leprosy) by ILEP Technical Commission (ITC)

From:  Felicity Bonham, ILEP, London, UK


Dear Pieter,

On behalf of Mr Douglas Soutar, General Secretary of ILEP and Secretary to the ILEP Technical Commission (ITC), I am sending a link to a model patient card/record developed by the ITC in response to demand. ILEP now recommends this can be taken as reference when leprosy endemic countries are developing or modifying their leprosy patient cards at national, sub-national and institutional levels: http://goo.gl/QGaiOw

This has been developed in response to need and a specific request made at the WHO Western Pacific Region’s Meeting of National Leprosy Programme Managers in early 2012.

 With advance thanks and all best wishes,

 Felicity

 

Felicity Bonham

PA to the General Secretary

International Federation of Anti-Leprosy Associations
Working together for a world without leprosy

Tel: +44 (0)20 7602 6925 – Fax: +44 (0)20 7371 1621 – Website: www.ilep.org.uk

To get our updates, like us on Facebook: ILEPAntiLeprosy


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Facial Erythematous Patches

Leprosy Mailing List – January 21,  2014 

Ref.:    (LML) Facial Erythematous Patches

From:   H K Kar, New Delhi, India


Dear Dr Pieter,

 

Referring to the letter of Dr. Rao concerning facial erythematous patches: we often encounter such problems of persistence of erythema on old treated patches of PB cases who also had history of type 1 reactions (T1R) for months together, particularly if the lesion is on the face.

 

If the histopathological examination after RFT still shows the features of T1R, few weeks of oral steroid is required instead of local steroid application. In addition, I always prefer to prescribe Sun blocking agent local application, (best is  calamine with zinc lotion) over the face to protect the lesion from UV light. The erythema very slowly disappears after a period of few months. In case of no histopathological features of T1R, only local calamine application is sufficient which should be applied for few months. Local application of topical calcineurin inhibitors like tacrolimus or pimecrolimus is worth trying at night.

 

Regards,

 

 

Dr (Prof.) H K Kar
Director and Med. Superintendent
P.G.I.M.E.R. and Dr Ram Manohar Lohia Hospital
Baba Kharag Singh Marg
New Delhi-110001

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Facial Erythematous Patches

Leprosy Mailing List – January 21,  2014 

Ref.:    (LML) Facial Erythematous Patches

From:  Thomas H. Rea, Los angelos, California, USA


 

Dear Dr. Scheuder,


Concerning Dr. Rao's patients: both photos show an erythema with a distinct purplish cast which we see not uncommonly in our Mexican-born patients who are having a reversal reaction.  The sharp margin in the gentleman patient is also consistent with a reversal reaction.  The lady appears to have edema of her lower lip, which might be attributed to a reversal reaction.  Biopsy is needed for definitive classification.

Regards,

 

Thomas H. Rea, M.D.

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 




This email is free from viruses and malware because avast! Antivirus protection is active.


Sunday, January 19, 2014

(LML) Dapsone syndrome

Leprosy Mailing List – January 19,  2014 

Ref.:    (LML) Dapsone Syndrome

From:  Ben Naafs, Munnekeburen, the Netherlands


Dear dr Jingquan Wang,

 

 

Thank you for your health wishes.

 

I think you treated indeed a dapsone syndrome and you were treating it well. The exfoliating dermatitis may come later than the other symptoms. After stopping the MDT and diminishing the steroids the immunity came back and the antigenic determinants were detected again and the original lesions showed again inflammation. This is visible. The ulceration I cannot explain. But I think will heal by itself.

 

Treat as new leprosy with a reversal reaction but refrain from dapsone. So treat with clofazimine and for instance minocyclin beside the rifampicin. Treat he reversal reaction with steroids for at least 6 months.

 

With regards,

 

 

Ben Naafs

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Dapsone syndrome

Leprosy Mailing List – January 19,  2014 

Ref.:    (LML) DDS syndrome

From:  David M. Scollard,  Baton Rouge, Louisiana, USA


Dear Pieter,

Regarding the dapsone syndrome, the following article was published recently in the New England Journal of Medicine, describing a genetic association with this syndrome.  The research was done in China and it appears that individuals of Chinese ancestry may be more likely to carry the allele(s) that put them at risk for this syndrome.

Zhang F.-R., Liu H., Irwanto A., et al.

HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome

N Engl J Med 2013; 369:1620-1628

Dapsone is an important medication for the treatment of leprosy, but a life-threatening drug hypersensitivity syndrome develops in some patients. In this report from China, an HLA-B locus is identified as a strong genetic risk factor for the syndrome.

 

Best wishes,

David

David M. Scollard, M.D., Ph.D.

Director

National Hansen’s Disease Programs

Tel:  225-756-3713 or 225-756-3776

Fax:  225-756-3819 (Clinical) or 225-756-3806 (Administration)

E-mail:  dscollard@hrsa.gov

Web:  www.hrsa.gov/hansens                 

Online Course:  http://www.hrsa.gov/hansensdisease/onlinecourseawareness.html

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) Dapsone syndrome

Leprosy Mailing List – January 19,  2014 

Ref.:    (LML) Dapsone syndrome

From:  Aguinaldo Gonçalves, Unicamp, Brazil


Dear Pieter,

First of all, a good and prosperous 2014 for everybody!

Thanks to your friends for the opportunity to share Doctor Wang' case. I would like to submit two short suggestions:

1- I could consider the possibility of applying some local healing stimuli, such  as laser therapy exposure(1) on the ulcerative lesion;

2- I don't know the conditions of the Chinese  prisons, but  it seems reasonable to  me to look for contacts (by skin, infusion  or drinking) with drugs that can promote leprosy reactions. Here in Brazil we have some experience with iodine products provoking ENL. I remember a published case of an alcohol addicted prisoner I have seen some years ago: working  as nursing auxiliary, he died because of repeatedly continuous mercurochrome ingestion.

Best regards,

Aguinaldo

Prof. Dr. Aguinaldo Gonçalves, MD, MSc, PhD
Full Professor, Public Health & Physical Activity, Unicamp, Brazil
A2 Researcher Professor, Preventive and Social Medicine,  PUC Campinas, Brazil
aguinaldogon@uol.com.br

Former National Director, Divison of Sanitary Dermatology, Ministry of Health
http://lattes.cnpq.br/8140651861738248

Ref.: (1) GONÇALVES G, GONÇALVES A, PADOVANI CR, PARIZOTTO NA.  Laser therapy applied to leprous and non-leprous ulcers healing: a clinical trial in out-patient units of Public Health Service  Hansenologia Inter. 2000, 25(2): 133-142, .


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


Monday, January 13, 2014

(LML) Nerve damage in leprosy: a case report

Leprosy Mailing List – January 13,  2014 

Ref.:    (LML) Nerve damage in leprosy: a case report.

From:  Salvatore Noto and Andrea Clapasson, Genua, Italy


 

Dear Pieter,

 

In attachment there is a PDF document with pictures of a lady with leprosy seen in Genoa, Italy. She is 41 years old and comes from Nigeria. The first seven pictures are clinical; the last two are histopathology images from biopsy of the sural nerve.

 

Skin lesions are vague and not easily recognized. There is advanced damage of the median, ulnar and posterior tibial nerves.

 

Thank you very much for circulating it to the leprosy mailing list. Any comment is welcome.

 

Salvatore Noto and Andrea Clapasson

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com




This email is free from viruses and malware because avast! Antivirus protection is active.


(LML) 29th Biennial Conference of Indian Association of Leprologists on March 28-30, 2014


Collapse

Chat

 
 
OfflineHerman-Joseph Kawuma
OfflineJaison Antonio Barreto
OfflineSalvatore Noto
Bernard Naafs
Brennan,Patrick
Fundacao para Controle da Hanseniase
Lucia
Steve Walker
Varage John Laka
WangJingquan
 
 
 
 
 
 
 
 
More
 
8 of 10
 
 
>
<
Why this ad?
Meuble Contemporain - www.bauhaus-classiques-design.com - Barcelona - Lounge Chair - Egg - Swan - Saarinen - Tulip - Jacobsen
512
Pop-out
Close
Next
Previous
Open
Open with
View all items
Download

1

LEPCON 2014

29th

Biennial Conference of Indian Association of Leprologists

Invitation to submit Abstracts

Participants are invited to submit abstracts for ORAL/POSTER/AWARD PAPERS

for “LEPCON 2014”. The submission deadline is January 15, 2014. Authors will be

notified of the results by the end of January 2014. Presenting Authors must register for

the conference by the time of submission of abstract, otherwise submitted abstracts will

not be considered further.

Important Notes for authors:

• Only online abstracts will be accepted. Kindly mail your abstracts at

lepcon2014@gmail.com

• The abstract review committee and the scientific committee reserve the right to

decide outcome of an abstract.

• Abstracts must be submitted in English. A “blind” selection process will be used.

No identifying features such as names of hospitals, medical schools, clinics or

cities may be listed in the title or text of the abstract.

• The title should be as brief as possible but long enough to clearly indicate the

nature of the study. Abbreviations must not be used in the title.

• The size of the abstract is limited to 300 words (excluding title)

Award papers: For Postgraduate (MD) Students only. Study should not have been

presented in any earlier conference or published in any journal at the time of submission

of the abstract for this conference. Presenting author must register for the conference

by the time of submission of abstract.

• Structure your abstract using the following subheadings:

o Title followed by name(s) of author, degrees, affiliations, contact phone

number and e mail id. Please underline and bold presenting authors’

name.

o Introduction & Objectives: A sentence describing the purpose of the study

o Materials & Methods: Describe your selection of observations or

experimental subjects precisely

o Results: Describe your results in a logical sequence

2

o Conclusions: Emphasize new and important aspects of the study and

conclusions that are drawn from them

• Failure to comply with the following requirements will lead to automatic

rejection of the submission:

o Check spelling and grammar carefully. Direct reproduction from your

electronically submitted abstract text means that any errors in spelling,

grammar or scientific data will be reproduced as submitted.

o Use generic names. Commercial drug names may not be used. Drugs

should be referred to by the active substance or pharmacological

designation.

o No mention of pharmaceutical company names should be included in the

abstract.

• The evaluation and scoring of the abstract (acceptance as poster or as

oral communication, or rejection) will be made according to a number of

criteria, including:

o Is the content interesting, informative, novel or important?

o Are the methods valid, the results relevant and the conclusions justified by

the data?

o Are the data presented with clarity and with appropriate structure?

o Is the text written according to proper English grammar and syntactic

style?

• The authors have to specify if they wish the submission to presented as:

3

o Poster presentation only

o Oral presentation only (that is, if rejection of the abstract, no

communication!)

o Poster or oral presentation

o Award paper session

-------------------------------------------------------------------------------------------------------

1 of 3
Abstract Submission LEPCON 2014.docx
Abstract Submission LEPCON 2014.docx

5 of 5
Lepcon 2014 First Announcement .pdf
Invitation letter LEPCON 2014 .pdf
Travel Info LEPCON 2014.docx
Registration form LEPCON 2014.docx
Abstract Submission LEPCON 2014.docx
Save to Drive
Close find bar
Next
Previous
Share
Close find bar
Next
Previous
Share
Close find bar
Next
Previous
Share
Close find bar
Next
Previous
Zoom in
Zoom out
Zoom to fit
Print
Share
Close find bar
Next
Previous
Zoom in
Zoom out
Zoom to fit
Print
Share
Lepcon 2014 First Announcement .pdf
Invitation letter LEPCON 2014 .pdf
Travel Info LEPCON 2014.docx
Registration form LEPCON 2014.docx
Abstract Submission LEPCON 2014.docx
Displaying Abstract Submission LEPCON 2014.docx.

Collapse

Chat

 
 
OfflineHerman-Joseph Kawuma
OfflineJaison Antonio Barreto
OfflineSalvatore Noto
Bernard Naafs
Bernard Naafs
Fundacao para Controle da Hanseniase
Lucia
Steve Walker
Varage John Laka
WangJingquan
 
 
 
 
 
 
 
 
More
 
7 of 9
 
 
>
<
Why this ad?
Meuble Contemporain - www.bauhaus-classiques-design.com - Barcelona - Lounge Chair - Egg - Swan - Saarinen - Tulip - Jacobsen
512
Pop-out
Close
Next
Previous
Open
Open with
View all items
Download

th

29 Biennial Conference of

Indian Association of Leprologists

28th - 30th March, 2014

Organized by :

Department of

Dermatology, Venereology & Leprology

Postgraduate Institute of Medical Education &

Research (PGIMER)

Chandigarh 160012, India

LEPCO N

2

th 29

CHANDIGARH 14

CEMENT

UN

NNO A TS

IR F

ÉS É

+

ɶ

É

äv

i

É

ÉÇ

¶

º

Éä´ p

É ºÉ´ÉÇ ¦É

Venue :

Lecture Theater Complex, Nehru Hospital,

PGIMER, Sector 12, Chandigarh

ACCOMMODATION AT CHANDIGARH

Note : Rates may change & Taxes are extra

Name of Hotel Tariff in Rs. Website/Email/Telephone

JW Marriott 9500-12500 0172-3955555

Sector-35-B

Park Plaza 5950-6800 0172-6600000

Sector 17

Hometel Chandigarh 3250-4500 9958592241

Phase 1, Indl. Area

Taj Chandigarh 7820-8880 08591542201

Sector 17-A

Hotel Mount View 8000- 9000 mountview@citcochandigarh.com

Sector-10 0172-4671111, 0172-2740544

Hotel Shivalik View 4800-10500 shivalikview@citcochandigarh.com

Sector 17-E 0172-2700001, 4672222, 4641888

Hotel Park View 1650-4500 Parkview@citcochandigarh.com

Sector 24-B 0172-2700050, 2728115,

4644492, 4644495-97

Hotel Piccadilly 3850-4850 Reservations@thepiccadily.com

Sector 22-B www.thepiccadily.com

0172-2707571, 0172-4315431

Hotel Aroma Complex 2795-4195 mail@hotelaroma.com

Sector 22-C www.hotelaroma.com

0172-4010000

Hotel Chandigarh 2000-4300 chandigarhbeckon@gmail.com

Beckon 0172-2676052

Sector-42

The Fern Residency, 4500-8000 res@fernresidencychandigarh.com

Phase-II, Indl. Area, 09216585132

Chandigarh

The Alitus Hotel, 3990-6990 info@thealtius.com

Phase-II, Indl. Area, 0172-5212121

Chandigarh

ORGANIZING COMMITTEE

Department of Dermatology, Venereology & Leprology

Room No. 8, Ist Floor, D-Block, Faculty Offices, Nehru Hospital

Postgraduate Institute of Medical Education & Research

(PGIMER) Chandigarh 160012, India

Ph: 0172-2756552, Mob. 9855005941

Email : lepcon2014@gmail.com

Conference Secretariat :

Organizing Secretary

Dr. Sunil Dogra

Patrons

Dr VM Katoch

DGICMR & Secretary DHR

Dr Y K Chawla

Director PGI

Dr Kiran Katoch

Scientific Committee Chairperson

Organizing Chairperson

Dr Sanjeev Handa Dr Sunil Dogra

Organizing Secretary

Joint Organizing Secretaries

Dr Vivek Malhotra

Dr Sendhil Kumaran

Dr Tarun Narang

Treasurer

Organizing Committee

Dr D Parsad

Dr S D Mehta

Dr G P Thami

Dr J S Kochar

Dr D S Chauhan

Dr Simrat Kaur

Dr Maleeka Sachdev

Dr Mala Bhalla

Dr Savita Yadav

Dr Rahul Mahajan

Dr Rajiv Kaura

Dr Rohit Bansal

Advisory Committee

Dr H K Noordeen

Dr V N Sehgal

Dr Bhushan Kumar

Dr Atul Shah

Dr G P Talwar

Dr H K Kar

Dr V K Sharma

Dr D M Thappa

Dr Indira Nath

Dr V V Pai

Dr C M Agarwal

Dr D Porichha

Dr Arun Inamadar

Dr Archana Singal

Dr P V Ranganadha Rao

Dr P Krishnamurthy

Dr M A Arif

Dr Sunil Anand

Dr P. Narasimha Rao

Dr Raghunatha Reddy

Dr Dipankar De

Dr P S Walia

Delegates can directly book their own accommodation.

The list of some hotels in Chandigarh near conference

venue is given above.

INVITATION

It gives us immense pleasure to inform you that

the Department of Dermatology, Venereology &

Leprology, Post Graduate Institute of Medical Education &

Research (PGIMER), Chandigarh, India has been given the

honour by the Indian Association of Leprologists (IAL) to

organize the “LEPCON 2014”, 29th Biennial Conference of

Indian Association of Leprologists on March 28-30, 2014.

Leprosy as a disease is indeed a problem which

requires a multi disciplinary approach. It still afflicts the

humanity, brings challenges and still arouses our curiosity.

There is no doubt that the global picture of leprosy is

different now than it was more than 30 years ago. It is true

that widespread use of MDT and improvements in patient

care led to a significant reduction in case numbers

worldwide and also to changes in the epidemiologic

features of the disease. However, it is clear that leprosy still

continues to be a major problem in many countries, India

having maximum burden of the case load. This is due to

the continued transmission of the disease, potential risk of

developing disabilities and deformities, with devastating

social and economic consequences. The Scientific

Program, under the experienced guidance of Dr Kiran

Katoch is being carefully prepared to make a serious effort

to satisfy the expectations of all by covering the

diagnostic, therapeutic, social, prevention of disabilities

and rehabilitation components. There would be an

opportunity to express your views and we invite you to

share your new approaches to a problem.

Chandigarh the host city as envisioned by India's

first Prime Minister, Sh. Jawahar Lal Nehru, was planned by

the famous French architect Le Corbusier. Picturesquely

located at the foothills of Shivalik, it is known as one of the

best example of urban planning and modern architect in

India. Chandigarh has many tourist attractions like Rose

Garden, Rock Garden, nearby Pinjore Garden and famous

hill station, Shimla. The weather in March is cool and light

wollen clothes are recommended.

Please make it convenient to attend the

conference, register early and ensure submission of

abstracts well in time. The organizing committee will strive

hard to make your stay pleasant and memorable. The

conference, we are sure will give you an additional

opportunity to meet old colleagues and make new friends.

With best wishes for a happy & successful New Year 2014.

Dr Sunil Dogra

(Organizing Secretary)

Dr Sanjeev Handa

(Organizing Chairperson)

TOPICS IN CONFERENCE

CME Theme : Sustaining Leprosy Elimination

Conference Topics

Ÿ Epidemiology

Ÿ Molecular Biology & Genetics

Ÿ Nerve function impairment

Ÿ Chemotherapy

Ÿ Drug Resistance

Ÿ Vaccines

Ÿ Chemoprophylaxis

Ÿ Rehabilitation

Ÿ Prevention of Disabilities

Ÿ Surveillance

Ÿ Reactions

Ÿ Dermatologists Role

Ÿ New Diagnostic tools

Ÿ Social aspects & Stigma

Ÿ Urban Leprosy

Ÿ Human Rights & Advocacy

Ÿ Reconstructive Surgeries

Ÿ Leprosy Control

Ÿ Role of NGOs

Ÿ Innovative approaches

REGISTRATION FORM

Name _________________________________________

Designation_________________________________________

Address _________________________________________

_________________________________________

_________________________________________

Mobile No. _________________________________________

E-mail _________________________________________

IAL Membership No.(Y/N) ______________________________

Accompanying Person(s)______________________________

#

#

#

29th Biennial Conference of

Indian Association of Leprologists

28th - 30th March, 2014

*Students must enclose a certificate from their Head of

Department. *Accompanying person: Spouse/Children only

Registration fee includes delegate kit, breakfast, lunch and

dinners during the conference.

Payment of Registration charges:

By Cheque/Demand draft in favour of “LEPCON 2014”

payable at Chandigarh, India. Please write your name and

address at the back of DD.

LEPCO N

2

th 29

CHANDIGARH 14

Abstract submission: All abstracts (oral/poster/award

papers for PG students) to be submitted only by e mail to

lepcon2014@gmail.com.

Last date of submission: January 15, 2014

CME credit hours

applied to PMC

Leprosy Quiz for PG Students :

Attractive prizes to win For more information :

pgimer.edu.in (Educational - Conference/CMEs)

Follow us on 8

Delegates Students/ Foreign

Accomp. person* Delegates

IAL Members Non-members

Before Rs 3500 Rs 4000 Rs 2500 150 USD

31-01-2014

After Rs 4500 Rs 5000 Rs 3500 200 USD

01-2-2014

Spot Rs 5000 Rs 5500 Rs 4000 250 USD

Registration

REGISTRATION FEES

1 of 2
Lepcon 2014 First Announcement .pdf
Lepcon 2014 First Announcement .pdf

1 of 5
Lepcon 2014 First Announcement .pdf
Invitation letter LEPCON 2014 .pdf
Travel Info LEPCON 2014.docx
Registration form LEPCON 2014.docx
Abstract Submission LEPCON 2014.docx
Close find bar
Next
Previous
Zoom in
Zoom out
Zoom to fit
Print
Share
Close find bar
Next
Previous
Zoom in
Zoom out
Zoom to fit
Print
Share
Close find bar
Next
Previous
Share
Close find bar
Next
Previous
Share
Close find bar
Next
Previous
Share
Lepcon 2014 First Announcement .pdf
Invitation letter LEPCON 2014 .pdf
Travel Info LEPCON 2014.docx
Registration form LEPCON 2014.docx
Abstract Submission LEPCON 2014.docx
Displaying Lepcon 2014 First Announcement .pdf.

Collapse

Chat

 
 
OfflineHerman-Joseph Kawuma
OfflineJaison Antonio Barreto
OfflineSalvatore Noto
Bernard Naafs
Brennan,Patrick
Fundacao para Controle da Hanseniase
Lucia
Steve Walker
Varage John Laka
WangJingquan
 
 
 
 
 
 
 
 
More
 
8 of 10
 
 
>
<
Why this ad?
Meuble Contemporain - www.bauhaus-classiques-design.com - Barcelona - Lounge Chair - Egg - Swan - Saarinen - Tulip - Jacobsen
512